Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Chiasma Raises $44 Million Series C to Fund Clinical Testing, Advance Technology.


Drs. Ansbert Gadicke and Edward Scolnick to Join the Board of Directors

BOSTON -- Chiasma chiasma (kīăz`mə): see crossing over.  Inc., a privately held company privately held company

A firm whose shares are held within a relatively small circle of owners and are not traded publicly.
 developing novel technologies for the enhanced oral delivery of proteins and small molecules, announced today the completion of a $44 million Series C financing. The proceeds will be used to take three programs into clinical development and to advance the company's core technology.

The financing was led by MPM MPM Multi-Processing Module (Apache)
MPM Manufacturing Process Management
MPM Milwaukee Public Museum
MPM MMW (Millimeter Wave) Power Module
MPM Master of Project Management (degree) 
 Capital, with participation by ARCH Venture Partners and existing investors Ofer Hi-tech Group and F-2 Ventures. As part of the financing, Drs. Ansbert Gadicke and Edward Scolnick of MPM Capital will join the company's board of directors and Robert Nelsen of ARCH Venture Partners will join the Board of Directors as an observer.

Dr. Edward Scolnick, Executive Advisor to MPM Capital, and former President of Merck Research Laboratories commented, "Chiasma's technology has the potential to revolutionize the oral delivery of protein- and peptide-based drugs. Poor absorption of these drugs currently require their injection by subcutaneous subcutaneous /sub·cu·ta·ne·ous/ (sub?ku-ta´ne-us) beneath the skin.

sub·cu·ta·ne·ous
adj. Abbr. s.c., SQ
Located, found, or placed just beneath the skin; hypodermic.
 or IV means. Although early, Chiasma's technology for oral delivery could eventually have a very significant impact on the utilization and effectiveness of protein and peptide drugs."

Guy Yachin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  of Chiasma Inc., commented, "We are thrilled to have a syndicate of world class investors. MPM and ARCH bring not only financial resources, but also significant industry and entrepreneurial experience."

In addition to Drs. Gadicke and Scolnick, the Chiasma Board of Directors includes Guy Yachin, Chief Executive Officer; Raul Cesan, former Chief Operating Officer Chief Operating Officer (COO)

The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president.
 of Schering Plough; Dr. Dalia Megiddo of InnoMed Ventures; Dr. Bard Geesaman of F2 Ventures and MPM Capital; and Yoav Doppelt of Ofer Hi-tech Group.

About Chiasma Inc.

Chiasma Inc. is developing novel technologies for the enhanced oral delivery of proteins and small molecules. Chiasma was founded by Dr. Shmuel Ben Sasson, together with Guy Yachin and Dr. Dalia Megiddo of InnoMed Ventures. The company will be based in Boston, MA with a research subsidiary in Jerusalem, Israel.

About MPM Capital

MPM Capital L.P. is a global investment management firm focused solely on life sciences investing. One of the largest investment management firms dedicated to the life sciences sector, MPM Capital has offices in Boston and San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . MPM's portfolio ranges from start-ups to large capitalization public companies, with a primary focus on biopharmaceutical and medical device companies nearing commercialization of products or those companies that already offer product-driven opportunities. The firm manages over $2.4 billion in assets through the MPM BioVentures Family of venture capital funds Venture Capital Funds

An investment fund that manages money from investors seeking private equity stakes in small and medium-size enterprises with strong growth potential.

Notes:
 and the MPM BioEquities public market funds. More information on MPM can be found at www.MPMCapital.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 15, 2006
Words:436
Previous Article:OXIS Phase IIA Licensed Compound Significantly Reduces Damage from Heart Attack in Diabetic Mice.
Next Article:Two Georgia School Districts Select Atlanta-Based Securiant to Provide Integrated Network Security.
Topics:



Related Articles
VALLEY RAIL FUNDING IN JEOPARDY : $58 MILLION STUDY REQUEST THREATENED BY MTA VOTE.
ARCHITECT'S PROGNOSIS: LET THE HEALING BEGIN.
SCHOOLS CALL BUDGET RISE JUST CATCH-UP.
POLITICIANS, EDUCATORS FACE UNPLEASANT OPTIONS.
BCRA: making a difference.
Public Education in the Crosshairs.
Coming to grips with nursing education funding: money for post-registration nursing education comes from a range of sources. Understanding the web of...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles